The correlation of serum long non‐coding RNA ANRIL with risk factors, functional outcome, and prognosis in atrial fibrillation patients with ischemic stroke

Zeng, Weixian; Jin, Jiaqi

doi:10.1002/jcla.23352

Cited by 16 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, reduced expression of lncRNA ANRIL is observed in AIS patients compared to controls, also it negatively correlates with inflammatory cytokines and disease severity in AIS patients 29 . However, lncRNA ANRIL is increased in atrial fibrillation patients with ischemic stroke compared with atrial fibrillation patients without ischemic stroke, also it positively correlates with the disease severity in atrial fibrillation patients with ischemic stroke 30 . Despite the clinical application of lncRNA ANRIL in cerebrovascular disease, no relevant study investigates its clinical role in neurodegenerative disease including PD patients.…”

Section: Discussionmentioning

confidence: 94%

Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

Yang¹,

Lin²,

Wang³

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background This study aimed to investigate the correlation of long non‐coding RNA antisense non‐coding RNA in the INK4 locus (lncRNA ANRIL) and its target microRNAs (microRNA‐34a (miR‐34a) and microRNA‐125a (miR‐125a)) with disease risk and severity of Parkinson’s disease (PD). Methods Seventy‐eight PD patients and 78 age‐/gender‐matched controls were consecutively enrolled. Their peripheral blood mononuclear cell samples were collected and proposed for the reverse‐transcription quantitative polymerase chain reaction to complete lncRNA ANRIL, miR‐34a, and miR‐125a measurements. Results LncRNA ANRIL was upregulated, while miR‐34a and miR‐125a were downregulated in PD patients compared to controls (all p < 0.001). Further, they all showed certain values for PD risk identification by ROC curve analyses, among which lncRNA ANRIL showed the highest AUC (AUC: 0.879, 95% CI: 0.824‐0.934). Furthermore, lncRNA ANRIL negatively correlated with miR‐34a (p = 0.016) and miR‐125a (p = 0.005) in PD patients, but not in controls. In addition, lncRNA ANRIL was observed to positively associate with UPDRS‐I score (p = 0.029), UPDRS‐III score (p = 0.006), and UPDRS‐IV score (p = 0.033), while negatively correlated with MMSE score (p = 0.003). These associations were less distinct as to miR‐34a and miR‐125a. Conclusion LncRNA ANRIL interacts with miR‐34a and miR‐125a in PD patients, and they all correlate with disease risk and severity of PD.

show abstract

Section: Discussionmentioning

confidence: 94%

Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

Yang¹,

Lin²,

Wang³

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Two studies analyzed datasets of Gene Expression Omnibus via bioinformatic analysis, respectively, and identified several genes which were involved in AF-related stroke ( 199 , 200 ). In addition, studies have shown that abnormal expression of non-coding RNAs, such as lncRNA ANRIL, hsa-miR-22-3p, was associated with functional outcome or prognosis in AF patients, and could potentially serve as potential biomarkers for AF-related IS ( 201 , 202 ). On the basis of current research, it can be expected that new and promising genetics biomarkers for AF-related IS will be further discovered in the near future.…”

Section: Novel Markers Of Genetics and Bioinformaticsmentioning

confidence: 99%

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation

Shang

Zhang

Guo

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide and results in a significantly increased ischemic stroke (IS) risk. IS risk stratification tools are widely being applied to guide anticoagulation treatment decisions and duration in patients with non-valvular AF (NVAF). The CHA2DS2-VASc score is largely validated and currently recommended by renowned guidelines. However, this score is heavily dependent on age, sex, and comorbidities, and exhibits only moderate predictive power. Finding effective and validated clinical biomarkers to assist in personalized IS risk evaluation has become one of the promising directions in the prevention and treatment of NVAF. A number of studies in recent years have explored differentially expressed biomarkers in NVAF patients with and without IS, and the potential role of various biomarkers for prediction or early diagnosis of IS in patients with NVAF. In this review, we describe the clinical application and utility of AF characteristics, cardiac imaging and electrocardiogram markers, arterial stiffness and atherosclerosis-related markers, circulating biomarkers, and novel genetic markers in IS diagnosis and management of patients with NVAF. We conclude that at present, there is no consensus understanding of a desirable biomarker for IS risk stratification in NVAF, and enrolling these biomarkers into extant models also remains challenging. Further prospective cohorts and trials are needed to integrate various clinical risk factors and biomarkers to optimize IS prediction in patients with NVAF. However, we believe that the growing insight into molecular mechanisms and in-depth understanding of existing and emerging biomarkers may further improve the IS risk identification and guide anticoagulation therapy in patients with NVAF.

show abstract

“…To be able to predict the risk of stroke in AF patients, Zeng et al monitored AF patients and compared the levels of the lncRNA ANRIL (antisense non-coding RNA in the INK4 locus) in the stroke group and a non-stroke group. The results showed that higher lncRNA ANRIL levels often correlate with a greater risk of stroke ( 98 ).…”

Section: Non-coding Rnas In Atrial Fibrillationmentioning

confidence: 99%

The Role of Exosomes and Their Cargos in the Mechanism, Diagnosis, and Treatment of Atrial Fibrillation

Huang

Deng

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common persistent arrhythmia, but the mechanism of AF has not been fully elucidated, and existing approaches to diagnosis and treatment face limitations. Recently, exosomes have attracted considerable interest in AF research due to their high stability, specificity and cell-targeting ability. The aim of this review is to summarize recent literature, analyze the advantages and limitations of exosomes, and to provide new ideas for their use in understanding the mechanism and improving the diagnosis and treatment of AF.

show abstract

The correlation of serum long non‐coding RNA ANRIL with risk factors, functional outcome, and prognosis in atrial fibrillation patients with ischemic stroke

Cited by 16 publications

References 26 publications

Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation

The Role of Exosomes and Their Cargos in the Mechanism, Diagnosis, and Treatment of Atrial Fibrillation

Contact Info

Product

Resources

About